DelveInsight’s, “Obesity - Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Obesity: Overview
Obesity can be described as the "New World Syndrome". Obesity is a multi-factorial disorder, which is often associated with many other significant diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers. The management of obesity will therefore require a comprehensive range of strategies focussing on those with existing weight problems and also on those at high risk of developing obesity. Hence, prevention of obesity during childhood should be considered a priority, as there is a risk of persistence to adulthood. Its prevalence is on continuous rise in all age groups of many of the developed countries in the world. Obesity, in simple terms, may be defined as a state of imbalance between calories ingested versus calories expended which would lead to excessive or abnormal fat accumulation. Obesity is not a single disorder but a heterogeneous group of conditions with multiple causes each of which is ultimately expressed as obese phenotype. Obesity involves complex a etiological links between the genetic, metabolic and neural frameworks on one hand and behavior, food habits, physical activity and socio-cultural factors on the other. Although obesity had a genetic component, it is not a simple genetic disorder. There is an underlying genetic predisposition to obesity on to which environmental factors are layered. Obesity is a serious, chronic medical condition, which is associated with a wide range of debilitating and life threatening conditions. The fact that obesity prevalence continues to increase at an alarming rate in almost all regions of the world is of major concern. Hence, an effective control of obesity requires the development of coherent strategies that tackle the main issues related to preventing: The development of over weight in normal weight individuals, the progression of over weight to obesity in those who are already over weight, weight regain in those who have been over weight or obese in the past but who have since lost weight and further worsening of a condition already established.
"Obesity- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.
This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Obesity Emerging Drugs
Tirzepatide: Eli Lily & Company
Tirzepatide also known as LY3298176, (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity. The dual agonist has also proven to be efficacious in tackling obesity and cardiovascular risk factors associated with T2D.
Danuglipron: Pfizer
Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.
XW003:Sciwind Biosciences
XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at Sciwind Biosciences. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in early clinical trials. . The drug is currently in phase 2 stage of development for the treatment of obesity.
Noiiglutide: Jiangsu Hansoh Pharmaceutical
Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.
MEDI 0382: MedImmune
MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1 and glucagon receptor activity. MEDI0382 was discovered and developed in MedImmune’s labs and is a dual agonist using natural amino acids. Currently, it is in phase 2 stage of development for the treatment of obesity.
Further product details are provided in the report……..
This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 80+ key companies which are developing the therapies for Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Eli Lily & Company.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Obesity: Overview
Pipeline Therapeutics
Therapeutic Assessment
Obesity– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tirzepatide: Eli Lily & Company
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Danuglipron: Pfizer
Drug profiles in the detailed report…..
Initial Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Obesity Key Companies
Obesity Key Products
Obesity- Unmet Needs
Obesity- Market Drivers and Barriers
Obesity- Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix
List of Table
Table 1: Total Products for Obesity
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Obesity
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Novartis
• Eli Lily &Company
• Scohia Pharma
• ERX Pharmaceuticals
• Amgen
• Allysta Pharmaceuticals
• Empros Pharma
• Innovent Biologics
• Boehringer Ingelheim
• Pfizer
